Trial Profile
An open, single-centre, controlled trial to investigate the efficacy and usability of published best practice to control glycaemia in hospitalised patients with type 2 diabetes.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary) ; Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 19 Apr 2012 Planned end date changed from 19 Dec 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
- 29 Jul 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 29 Jul 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).